NVX Relative Valuation
NVX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVX is overvalued; if below, it's undervalued.
Historical Valuation
NOVONIX Ltd (NVX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.39 is considered Undervalued compared with the five-year average of -33.80. The fair price of NOVONIX Ltd (NVX) is between 3.40 to 15.30 according to relative valuation methord. Compared to the current price of 1.58 USD , NOVONIX Ltd is Undervalued By 53.52%.
Relative Value
Fair Zone
3.40-15.30
Current Price:1.58
53.52%
Undervalued
0.00
PE
1Y
3Y
5Y
46.19
EV/EBITDA
NOVONIX Ltd. (NVX) has a current EV/EBITDA of 46.19. The 5-year average EV/EBITDA is -27.61. The thresholds are as follows: Strongly Undervalued below -144.82, Undervalued between -144.82 and -86.22, Fairly Valued between 31.00 and -86.22, Overvalued between 31.00 and 89.61, and Strongly Overvalued above 89.61. The current Forward EV/EBITDA of 46.19 falls within the Overvalued range.
-5.57
EV/EBIT
NOVONIX Ltd. (NVX) has a current EV/EBIT of -5.57. The 5-year average EV/EBIT is -9.42. The thresholds are as follows: Strongly Undervalued below -101.05, Undervalued between -101.05 and -55.24, Fairly Valued between 36.40 and -55.24, Overvalued between 36.40 and 82.22, and Strongly Overvalued above 82.22. The current Forward EV/EBIT of -5.57 falls within the Historic Trend Line -Fairly Valued range.
2.39
PS
NOVONIX Ltd. (NVX) has a current PS of 2.39. The 5-year average PS is 66.30. The thresholds are as follows: Strongly Undervalued below -99.43, Undervalued between -99.43 and -16.56, Fairly Valued between 149.17 and -16.56, Overvalued between 149.17 and 232.03, and Strongly Overvalued above 232.03. The current Forward PS of 2.39 falls within the Historic Trend Line -Fairly Valued range.
-124.51
P/OCF
NOVONIX Ltd. (NVX) has a current P/OCF of -124.51. The 5-year average P/OCF is -54.36. The thresholds are as follows: Strongly Undervalued below -205.79, Undervalued between -205.79 and -130.08, Fairly Valued between 21.35 and -130.08, Overvalued between 21.35 and 97.07, and Strongly Overvalued above 97.07. The current Forward P/OCF of -124.51 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
NOVONIX Ltd. (NVX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
NOVONIX Ltd (NVX) has a current Price-to-Book (P/B) ratio of 4.82. Compared to its 3-year average P/B ratio of 3.00 , the current P/B ratio is approximately 60.87% higher. Relative to its 5-year average P/B ratio of 4.75, the current P/B ratio is about 1.46% higher. NOVONIX Ltd (NVX) has a Forward Free Cash Flow (FCF) yield of approximately -40.72%. Compared to its 3-year average FCF yield of -29.60%, the current FCF yield is approximately 37.56% lower. Relative to its 5-year average FCF yield of -20.45% , the current FCF yield is about 99.10% lower.
4.82
P/B
Median3y
3.00
Median5y
4.75
-40.72
FCF Yield
Median3y
-29.60
Median5y
-20.45
Competitors Valuation Multiple
The average P/S ratio for NVX's competitors is 16.85, providing a benchmark for relative valuation. NOVONIX Ltd Corp (NVX) exhibits a P/S ratio of 2.39, which is -85.8% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NVX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NVX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NOVONIX Ltd (NVX) currently overvalued or undervalued?
NOVONIX Ltd (NVX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.39 is considered Undervalued compared with the five-year average of -33.80. The fair price of NOVONIX Ltd (NVX) is between 3.40 to 15.30 according to relative valuation methord. Compared to the current price of 1.58 USD , NOVONIX Ltd is Undervalued By 53.52% .
What is NOVONIX Ltd (NVX) fair value?
NVX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of NOVONIX Ltd (NVX) is between 3.40 to 15.30 according to relative valuation methord.
How does NVX's valuation metrics compare to the industry average?
The average P/S ratio for NVX's competitors is 16.85, providing a benchmark for relative valuation. NOVONIX Ltd Corp (NVX) exhibits a P/S ratio of 2.39, which is -85.80% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for NOVONIX Ltd (NVX) as of Jan 08 2026?
As of Jan 08 2026, NOVONIX Ltd (NVX) has a P/B ratio of 4.82. This indicates that the market values NVX at 4.82 times its book value.
What is the current FCF Yield for NOVONIX Ltd (NVX) as of Jan 08 2026?
As of Jan 08 2026, NOVONIX Ltd (NVX) has a FCF Yield of -40.72%. This means that for every dollar of NOVONIX Ltd’s market capitalization, the company generates -40.72 cents in free cash flow.
What is the current Forward P/E ratio for NOVONIX Ltd (NVX) as of Jan 08 2026?
As of Jan 08 2026, NOVONIX Ltd (NVX) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of NOVONIX Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for NOVONIX Ltd (NVX) as of Jan 08 2026?
As of Jan 08 2026, NOVONIX Ltd (NVX) has a Forward P/S ratio of 2.39. This means the market is valuing NVX at $2.39 for every dollar of expected revenue over the next 12 months.